Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Single activity fee to increase by 4p from November

Contractors in England will receive a single activity fee of £1.29 per item from next month, the Pharmaceutical Services Negotiating Committee (PSNC) has confirmed.

The 4p increase reflects “a need to address an under-delivery on fees due”, PSNC said in a statement yesterday (October 19).

The single activity fee was introduced along with the pharmacy funding cuts in England in December 2016, and replaced payouts for dispensing, practice payments, and the electronic prescription service (EPS).

It was first set at £1.13 per item, rising to £1.25 in April 2017.

The latest increase will be reflected in November’s drug tariff and in contractors scheduled payments in February, PSNC said.

The single activity fee “will be kept under review” and further amends will be considered as more data becomes available, the negotiator added.

How are you coping with the pharmacy funding cuts?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD009008

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel